BTAIBioXcel Therapeutics, Inc.
0.8038USD-2.85%Mkt Cap: 25.16M $P/E: —3d ago
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immu…
Industry Peers
Drug Manufacturers - Specialty & Generic$65.19BUSDP/E 23.7
$58.06BUSD
$43.98BUSDP/E 20.4
$43.51BUSDP/E 62.2
$29.89BUSDP/E 12.7
$32.12BUSDP/E 12.7
$22.01BUSDP/E 18.4
$18.75BUSD
$15.34BUSDP/E 117.3
$14.67BUSDP/E 26.4
$15.51BUSDP/E 22.3
$11.98BUSD
$10.15BUSDP/E 29.7
$8.66BUSDP/E 19.0
$8.11BUSDP/E 127.2
$7.88BUSD
$6.53BUSDP/E 23.9
$6.24BUSDP/E 37.3
$6.14BUSDP/E 49.0
$6.08BUSDP/E 79.8
| Headline | Source | Time |
|---|---|---|
Older | ||
 BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +3.92% and -46.47%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates BioMarin (BMRN) delivered earnings and revenue surprises of +25.00% and +7.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||